Advances in pharmacotherapy for adolescent obesity
CHUN wan-shun
WANG He
HU Meng-jie
MEI Zi-xuan
WANG Tian-ai
GONG Cheng
PAN Ding-yu
LI Zhen
Abstract：In recent years,weight-loss medications such as glucagon-like peptide-1 receptor agonist,and PHEN/TPM have brought breakthrough progress in the treatment of adolescent obesity.By targeting appetite control centers or inhibiting neurotransmitter re-uptake,they significantly improve clinical outcomes in obese adolescents.These drugs not only effectively reduce body weight but also ameliorate metabolic issues such as insulin resistance and dyslipidemia.However,their long-term safety,cost accessibility,and individualized medication strategies still require improvement.Moving forward,it is necessary to advance long-term follow-up studies and establish real-world databases to support personalized treatment.Medication therapy should be integrated with lifestyle interventions,building a"family-medical-society"tripartite management model to achieve precise prevention and management of adolescent obesity.
Keywords：adolescent obesityweight-loss pharmacothera-pydrug safetyglucagon-like peptide-1 receptor agonist
Publication Date：2025-10-01
Online Publishing Date：2025-12-09(First online date of this platform, not the publication date of the document)
Pages：4( 1177-1180 )